Seven Firms Lead on $8.6 Billion Deal for Drugmaker Elan

, The Am Law Daily

   |0 Comments

Cadwalader, Fried Frank, Gibson Dunn, Morgan Lewis, Sullivan & Cromwell, and leading Irish firms A&L Goodbody and Dillon Eustace are advising on the $6.7 billion cash-and-stock sale of Dublin-based biotechnology company Elan to U.S. generic pharmaceutical firm Perrigo, which will also assume $1.9 billion of the Irish drugmaker's debt. The transaction marks the end of a months-long engagement by corporate and litigation lawyers at Cadwalader on Elan's behalf.

This article has been archived, and is no longer available on this website.

View this content exclusively through LexisNexis® Here

Not a LexisNexis® Subscriber?

Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202612947666

Thank you!

This article's comments will be reviewed.